AN2 Therapeutics, Inc.
ANTX
$1.07
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.63% | 55.23% | 35.92% | 55.49% | 23.70% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -49.62% | 23.03% | 23.96% | 30.99% | -23.41% |
| Change in Net Operating Assets | 654.06% | -113.23% | 30.44% | 194.53% | -112.76% |
| Cash from Operations | 46.91% | 47.17% | 39.61% | 69.11% | -1.75% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -67.36% | -64.56% | -65.03% | -1,738.10% | 129.97% |
| Cash from Investing | -67.36% | -64.56% | -65.03% | -1,738.10% | 129.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 108.70% | -- | -81.38% | -- | -99.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 108.70% | -- | -81.38% | 100.00% | -99.97% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.22% | -185.02% | -115.10% | 28.38% | 182.17% |